GeoVax_logo_tag_Reg.jpg 

GeoVax Labs, Inc.
1900 Lake Park Drive, Suite 380
Smyrna, GA 30080

https://www.geovax.com/

You Might Also Like...

Key Points About GeoVax

Blogs: GOVX

Recent News Releases

GeoVax Labs, Inc. (GOVX-OTC)

GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a uniquely-positioned clinical-stage biotechnology company developing preventative and therapeutic human vaccines against infectious diseases and cancer. The Company’s patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) technology is the foundation for producing non-infectious virus-like particles (VLPs) from the cells of the individual receiving the vaccine. Producing VLPs in a vaccinated individual mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear, while maintaining the safety characteristics of a replication-defective vector. GeoVax is focused on developing vaccines against human immunodeficiency virus (HIV), Zika virus (ZIKV), hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa), and malaria. The Company also has programs to develop a vaccine to treat chronic Hepatitis B virus (HBV) infection and to apply its MVA-VLP technology to cancer immunotherapy (immuno-oncology). GeoVax believes its expertise is complementary to a range of other human diseases for which there is an unmet medical need, and consequently, plans to expand its pipeline.

* The Corporate Snapshot was last updated on October 18, 2017.


 

Latest Research

GeoVax_Update_Cover_image_10-18-17.gif

Download Update

10-18-17

Past Research

GeoVax_EIO_Cover_Image_1.png

Download GeoVax Report

06-15-17

Key Points About GeoVax

Blogs: GOVX